---
title: "Semaglutide and Panic Attacks: FAERS Disproportionality, Notoriety Bias, and Evidence Triangulation"
id: "pubmed-42946127"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42946127"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42946127/"
doi: "10.1002/pds.70517"
published_at: "2026-11-01T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Semaglutide and Panic Attacks: FAERS Disproportionality, Notoriety Bias, and Evidence Triangulation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42946127
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42946127/)
- **DOI:** [10.1002/pds.70517](https://doi.org/10.1002%2Fpds.70517)
- **Published At:** 2026-11-01T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The investigators performed an active-comparator disproportionality analysis of the **FAERS** database from 2018Q1–2024Q4, focusing on reports where **semaglutide**, dulaglutide or empagliflozin were the primary suspect drugs. - Panic attack events were identified using the MedDRA preferred term; the source reported counts and proportions for each comparator group (semaglutide 87/33,267; dulaglutide 28/54,282; empagliflozin 13/25,380). - Crude reporting odds ratios (RORs) versus dulaglutide and empagliflozin were about fivefold; adjustment for age, sex and indication reduced these to approximately 2.7–2.8 (aRORs). - Temporal analyses separated reports before July 1, 2023 and compared 2018–2022 with 2023–2024; the pre-warning period produced smaller, non-significant adjusted signals. - Panic-attack reports per 10,000 **semaglutide** reports rose markedly from 6.7 (2018–2022) to 42.0 (2023–2024); a drug-by-period interaction reached statistical significance (p = 0.007), consistent with increased reporting after heightened attention. - Using all other primary-suspect drugs in FAERS as the reference, the overall adjusted ROR was 1.48 and was 0.76 before July 1, 2023. - A parallel systematic review (to 24 Nov 2025) screened randomized, cohort and cross-sectional studies plus case reports; across 12 included studies, trials and active-comparator cohorts did not show a consistent increase in panic attacks or anxiety-related outcomes. - The authors concluded that crude disproportionality suggested a signal, but attenuation after covariate adjustment and a temporal surge after mid-2023 align with **notoriety bias**. - The report emphasizes that disproportionality analysis is hypothesis-generating, cannot estimate incidence, and cannot establish causality; the source lists no conflicts of interest and provides a PMCID for the full text.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42946127/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42946127%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42946127/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42946127/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42946127/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42946127/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42946127/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42946127/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42946127%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42946127%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42946127/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42946127/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42946127/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42946127/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Wiley full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--media.wiley.com-assets-7388-69-wiley-full-text.png) Wiley ](https://doi.org/10.1002/pds.70517 "See full text options at Wiley")[ Free PMC article ](https://pmc.ncbi.nlm.nih.gov/articles/pmid/42946127/ "Free full text at PubMed Central") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42946127/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42946127/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42946127/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42946127/#abstract) * [ Plain language summary ](https://pubmed.ncbi.nlm.nih.gov/42946127/#plain-language-summary) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42946127/#conflict-of-interest) * [ Figures ](https://pubmed.ncbi.nlm.nih.gov/42946127/#figures) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42946127/#references) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42946127/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42946127/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42946127/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42946127/#linkout) Title & authors Abstract Plain language summary Conflict of interest statement Figures References MeSH terms Substances Related information LinkOut - more resources Pharmacoepidemiol Drug Saf Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pharmacoepidemiol+Drug+Saf%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Pharmacoepidemiol+Drug+Saf%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42946127/) . 2026 Nov;35(11):e70517. doi: 10.1002/pds.70517. # Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance [Ben Melamed](https://pubmed.ncbi.nlm.nih.gov/?term=Melamed+B&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Mahak Parsi-Zahabi](https://pubmed.ncbi.nlm.nih.gov/?term=Parsi-Zahabi+M&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Mohammad Ali Omrani](https://pubmed.ncbi.nlm.nih.gov/?term=Omrani+MA&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Bala Swetha Baskaran](https://pubmed.ncbi.nlm.nih.gov/?term=Baskaran+BS&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Lujain Ez Eddin](https://pubmed.ncbi.nlm.nih.gov/?term=Eddin+LE&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Nazgol Kermanshahi](https://pubmed.ncbi.nlm.nih.gov/?term=Kermanshahi+N&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Niaz Chalabianloo](https://pubmed.ncbi.nlm.nih.gov/?term=Chalabianloo+N&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Flory Tsobo Muanda](https://pubmed.ncbi.nlm.nih.gov/?term=Muanda+FT&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-2 "ICES Western, Kidney, Dialysis & Transplantation Research Program, London, Ontario, Canada.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-3 "Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#full-view-affiliation-4 "London Health Sciences Centre, Lawson Health Research Institute, London, Ontario, Canada.") Affiliations Expand ### Affiliations * 1 Department of Physiology and Pharmacology, Western University, London, Ontario, Canada. * 2 ICES Western, Kidney, Dialysis & Transplantation Research Program, London, Ontario, Canada. * 3 Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. * 4 London Health Sciences Centre, Lawson Health Research Institute, London, Ontario, Canada. * PMID: **42946127** * PMCID: [ PMC13713200 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13713200/) * DOI: [ 10.1002/pds.70517 ](https://doi.org/10.1002/pds.70517) Item in Clipboard # Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance Ben Melamed et al. Pharmacoepidemiol Drug Saf. 2026 Nov. Show details Display options Display options Format Abstract PubMed PMID Pharmacoepidemiol Drug Saf Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pharmacoepidemiol+Drug+Saf%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Pharmacoepidemiol+Drug+Saf%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42946127/) . 2026 Nov;35(11):e70517. doi: 10.1002/pds.70517. ### Authors [Ben Melamed](https://pubmed.ncbi.nlm.nih.gov/?term=Melamed+B&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Mahak Parsi-Zahabi](https://pubmed.ncbi.nlm.nih.gov/?term=Parsi-Zahabi+M&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Mohammad Ali Omrani](https://pubmed.ncbi.nlm.nih.gov/?term=Omrani+MA&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Bala Swetha Baskaran](https://pubmed.ncbi.nlm.nih.gov/?term=Baskaran+BS&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Lujain Ez Eddin](https://pubmed.ncbi.nlm.nih.gov/?term=Eddin+LE&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Nazgol Kermanshahi](https://pubmed.ncbi.nlm.nih.gov/?term=Kermanshahi+N&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Niaz Chalabianloo](https://pubmed.ncbi.nlm.nih.gov/?term=Chalabianloo+N&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada."), [Flory Tsobo Muanda](https://pubmed.ncbi.nlm.nih.gov/?term=Muanda+FT&cauthor_id=42946127)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-1 "Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-2 "ICES Western, Kidney, Dialysis & Transplantation Research Program, London, Ontario, Canada.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-3 "Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42946127/#short-view-affiliation-4 "London Health Sciences Centre, Lawson Health Research Institute, London, Ontario, Canada.") ### Affiliations * 1 Department of Physiology and Pharmacology, Western University, London, Ontario, Canada. * 2 ICES Western, Kidney, Dialysis & Transplantation Research Program, London, Ontario, Canada. * 3 Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. * 4 London Health Sciences Centre, Lawson Health Research Institute, London, Ontario, Canada. * PMID: **42946127** * PMCID: [ PMC13713200 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13713200/) * DOI: [ 10.1002/pds.70517 ](https://doi.org/10.1002/pds.70517) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Purpose:** To evaluate how confounding by indication and notoriety bias shape the apparent semaglutide-panic attack signal in the FDA Adverse Event Reporting System (FAERS) and to interpret this signal using an evidence-triangulation framework integrating randomized and observational studies. **Methods:** We conducted an active-comparator restricted disproportionality analysis of FAERS (2018Q1-2024Q4), including individual case safety reports in which semaglutide, dulaglutide or empagliflozin was the primary suspect drug. Panic attack was identified using the MedDRA preferred term. Crude and adjusted reporting odds ratios (RORs, aRORs) with 95% confidence intervals (CIs) were estimated using logistic regression, adjusting for age, sex and indication (Type 2 diabetes, obesity/weight management). Notoriety bias was assessed using prespecified temporal analyses (analyses restricted to reports received before July 1, 2023 and a drug-by-period comparison of 2018-2022 with 2023-2024) and reporting proportions per 10 000 reports. A sensitivity analysis used all other primary-suspect drugs in FAERS as the reference set. In parallel, we conducted a systematic review (MEDLINE, Embase, CENTRAL to November 24, 2025) of randomized trials, cohort and cross-sectional studies, pharmacovigilance analyses and case reports reporting panic attacks or acute anxiety outcomes with semaglutide. **Results:** Among 33 267 semaglutide, 54 282 dulaglutide and 25 380 empagliflozin reports, panic attacks were recorded in 87 (0.26%), 28 (0.05%) and 13 (0.05%) cases, respectively. Crude RORs were 5.08 (95% CI 3.32-7.78) versus dulaglutide and 5.12 (95% CI 2.86-9.17) versus empagliflozin, attenuating after adjustment to 2.82 (95% CI 1.74-4.56) and 2.75 (95% CI 1.41-5.36). In the pre-warning period crude RORs were 2.24 (95% CI 1.23-4.07) and 2.15 (95% CI 1.00-4.58), attenuating to 1.38 (95% CI 0.69-2.75) and 1.14 (95% CI 0.48-2.68) after adjustment. Panic-attack reports per 10 000 semaglutide reports rose from 6.7 in 2018-2022 to 42.0 in 2023-2024 (drug-by-period interaction p = 0.007). Against all other primary-suspect drugs, the aROR was 1.48 (95% CI 1.18-1.87) overall and 0.76 (95% CI 0.48-1.18) before July 1, 2023. Across 12 studies, randomized trials and active-comparator observational cohorts did not show a consistent increase in panic attacks or anxiety-related outcomes. **Conclusions:** Crude FAERS analyses suggested a semaglutide-panic attack signal that attenuated after adjustment was no longer significant before the July 2023 regulatory communication and rose sharply thereafter in a pattern consistent with notoriety bias. Triangulation with randomized trials and active-comparator observational studies does not support a consistent pharmacological association. Disproportionality analyses are hypothesis-generating and cannot estimate incidence or establish causality. This case study illustrates how active-comparator design, temporal assessment of notoriety bias and evidence triangulation can improve the interpretation of post-marketing safety signals. **Keywords:** FAERS; GLP‐1 receptor agonists; confounding by indication; notoriety bias; panic attack; pharmacovigilance; semaglutide. ## Plain language summary This study investigated whether the diabetes and weight‐loss drug semaglutide (commonly known as Ozempic or Wegovy) increases the risk of panic attacks. Researchers analyzed patient safety data from the FDA Adverse Event Reporting System (FAERS) spanning 2018 through 2024. While the raw numbers initially showed that panic attacks were reported more often with semaglutide than with other medications (like dulaglutide or empagliflozin), this connection weakened significantly once researchers adjusted for patient age, sex and the specific reason for taking the drug. Crucially, the surge in panic attack reports occurred only after mid‐2023, coinciding with heightened media attention and regulatory reviews regarding the mental health impacts of GLP‐1 drugs. This pattern is consistent with ‘notoriety bias’, meaning that greater public awareness may have led to more reports rather than the drug itself causing more panic attacks. However, this type of data can neither prove nor rule out a true effect. Furthermore, a review of 12 studies, including pooled clinical trial data and real‐world observational studies, found no consistent evidence linking semaglutide to increased panic attacks or anxiety. Overall, the available evidence does not show a consistent link between semaglutide and panic attacks, although an association with panic attacks cannot be excluded. © 2026 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement The authors declare no conflicts of interest. ## Figures [ ![FIGURE 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6db/13713200/09be407940c9/PDS-35-e70517-g001.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6db/13713200/d29907ca5955/PDS-35-e70517-g001.webp) ** FIGURE 1 ** Crude and adjusted reporting odds… ** FIGURE 1 ** Crude and adjusted reporting odds ratios for panic attack reports with semaglutide compared… **FIGURE 1** Crude and adjusted reporting odds ratios for panic attack reports with semaglutide compared with active
## Related Clinical Research

- [SGLT2 inhibitors vs GLP-1 RAs and osteoarthritis risk in type 2 diabetes: a multi-institutional co](https://medichelpline.com/clinical-feed/plos-one-16-comparative-effects-of-sglt2-inhibitors-and-glp-1-receptor-agonists-on.md)
- [GLP‑1 and Dual GIP/GLP‑1 Receptor Agonists: Psychopharmacology and Potential Neuropsychiatric Effe](https://medichelpline.com/clinical-feed/pubmed-42624955.md) (DOI: 10.1007/s11920-026-01709-w)
- [Finerenone Slows eGFR Decline in Chronic Kidney Disease Patients Without Diabetes](https://medichelpline.com/clinical-feed/pubmed-42246672.md) (DOI: 10.1056/NEJMoa2604625)
- [Retatrutide: A New Approach for Easing Knee Osteoarthritis Pain](https://medichelpline.com/clinical-feed/medical-news-today-0-new-weight-loss-drug-eases-knee-osteoarthritis-pain-in-major-trials.md)
- [Retatrutide and obstructive sleep apnea: phase 3 trials show AHI improvements](https://medichelpline.com/clinical-feed/medical-news-today-0-experimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.